Enhancing the effectiveness of a breast cancer treatment
Breast cancers expressing the protein HER2 have a particularly poor prognosis. Treatment with trastuzumab (Herceptin) benefits some patients with HER2-positive breast cancer, but it is not as effective as had been hoped. Researchers are therefore seeking ways to enhance the effectiveness of trastuzumab. In this context, a team of researchers led by Ronald Levy, at Stanford University, Stanford, has identified a sequential treatment regimen that enhances the effectivenss of trastuzumab in xenotransplant models of breast cancer.
Trastuzumab is a molecule known as an antibody that binds to HER2. Binding of trastuzumab to HER2-positive tumor cells recruits immune cells such as natural killer cells to the tumor cells. Upon encountering encountering trastuzumab-coated, HER2-overexpressing tumor cells, natural killer cells become activated and kill the tumor cells. Levy and colleagues found that upon encountering trastuzumab-coated, HER2-overexpressing breast cancer cells, human NK cells upregulated expression of the protein CD137.
Moreover, stimulating trastuzumab-activated human NK cells with an agonistic antibody specific for CD137 led to breast cancer cell killing in vitro and in xenotransplant models of breast cancer. They therefore suggest that trastuzumab treatment followed by administration of an antibody that activates natural killer cells (for example, an antibody that targets CD137) could provide a more effective way to treat patients with HER2-positive breast cancer than trastuzumab alone.
More information: www.jci.org/articl… e3bcddb314c8
Provided by Journal of Clinical Investigation
-
New therapy for HER2-positive breast cancer developed
Jul 26, 2011 |
not rated yet |
0
-
Antibody-guided drug shows encouraging activity in metastatic breast cancer
Dec 12, 2009 |
not rated yet |
0
-
Trastuzumab and chemotherapy improved survival in HER2-postive breast and brain cancer patients
Jul 18, 2011 |
not rated yet |
0
-
Breast cancer treatment shows benefit for women with small, localized disease
Jun 28, 2011 |
not rated yet |
0
-
Genetic approach provides new insight into trastuzumab resistance in breast cancer
Oct 15, 2007 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
Pressure-volume curve: Elastic Recoil Pressure don't make sense
8 hours ago
-
If you became brain-dead, would you want them to pull the plug?
May 17, 2013
-
MRI bill question
May 15, 2013
-
Ratio of Hydrogen of Oxygen in Dessicated Animal Protein
May 13, 2013
-
Alcohol and acetaminophen
May 13, 2013
-
Marie Curie's leukemia
May 13, 2013
- More from Physics Forums - Medical Sciences
More news stories
New colonoscope provides ground-breaking view of colon
A ground-breaking advance in colonoscopy technology signals the future of colorectal care, according to research presented today at Digestive Disease Week(DDW). Additional research focuses on optimizing the minimal withdrawal ...
Cancer
1 hour ago |
not rated yet |
0
ASCO: combo antibody therapy effective for melanoma
(HealthDay)—Concurrent use of two immune checkpoint antibodies—ipilimumab and nivolumab—may be effective for the treatment of advanced melanoma, according to a proof-of-principal study presented in ...
Cancer
20 hours ago |
not rated yet |
0
Risk factors ID'd for poor cutaneous cell CA outcomes
(HealthDay)—The risks of metastasis and death associated with cutaneous squamous cell carcinoma (CSCC) are low, but significant, and risk factors for poor outcome include tumor diameter, invasion beyond ...
Cancer
21 hours ago |
not rated yet |
0
|
Physical & emotional impairments common, often untreated in people with cancer
A new review finds cancer survivors suffer a diverse and complex set of impairments, affecting virtually every organ system. Writing in CA: A Cancer Journal for Clinicians, Julie Silver, M.D., associate professor at Harvar ...
Cancer
May 17, 2013 |
not rated yet |
0
Calif. doc with 'cancer cure' gets 14 years prison (Update)
(AP)—A California doctor has been sentenced to 14 years in federal prison for bilking her patients out of more than $1 million by promising that an herbal supplement could cure late-stage cancer and other diseases.
Cancer
May 17, 2013 |
not rated yet |
0
New research identifies risks, interventions for children's GI health
An increasing number of U.S. children are experiencing gastrointestinal issues that require interventions to resolve, according to research presented at Digestive Disease Week (DDW).
AIDS science at 30: 'Cure' now part of lexicon
Big names in medicine are set to give an upbeat assessment of the war on AIDS on Tuesday, 30 years after French researchers identified the virus that causes the disease.
For combat veterans suffering from post-traumatic stress disorder, 'fear circuitry' in the brain never rests
Chronic trauma can inflict lasting damage to brain regions associated with fear and anxiety. Previous imaging studies of people with post-traumatic stress disorder, or PTSD, have shown that these brain regions can over-or ...
Melon focus headband turns to Kickstarter for rollout plans
(Medical Xpress)—What if the quality of your work depends more on your focus on the piano keys or canvas or laptop than your musical or painting or computing skills? If target users can be convinced, they ...
Temporal processing in the olfactory system
The neural machinery underlying our olfactory sense continues to be an enigma for neuroscience. A recent review in Neuron seeks to expand traditional ideas about how neurons in the olfactory bulb might encode information about ...
Now we know why old scizophrenia medicine works on antibiotics-resistant bacteria
In 2008 researchers from the University of Southern Denmark showed that the drug thioridazine, which has previously been used to treat schizophrenia, is also a powerful weapon against antibiotic-resistant bacteria such as ...